Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK [0.03%]
英国2型糖尿病患者达到复合治疗终点的每年药房费用： Tirzepatide与司美格鲁肽(subcutaneous semaglutide 1 mg)靶向成本分析
Naresh Kanumilli,Beatrice Osumili,Jerome Evans et al.
Naresh Kanumilli et al.
Introduction: Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagog...
Clinical and healthcare burden of myotonic dystrophy type 1 (DM1) in the United States: a claims-based study [0.03%]
美国肌迟缓自体免疫症Ⅰ型(DM1)的临床及医疗负担（基于保险理赔数据分析）
Johanna I Hamel,Mihail Samnaliev,Lauren Do et al.
Johanna I Hamel et al.
Objectives: Myotonic dystrophy type 1 (DM1) is a multi-systemic disease affecting skeletal and smooth muscle, the eye, brain, and heart. No disease-modifying therapies are available. Prior studies on clinical care and eco...
Enhanced patient outcomes and improved budget impact from increased PFO diagnostic testing in cryptogenic stroke workup: a US hospital perspective [0.03%]
增加卵圆孔未闭检测可改善隐源性卒中诊疗的患者预后并优化医院预算——美国医院视角
John J Volpi,Giorgia Tiozzo,Jet Neervoort et al.
John J Volpi et al.
Aim: Limited research exists on the hospital-level costs and reimbursement associated with PFO diagnostic testing. This study estimates the impact of fully implementing guideline-driven PFO diagnostic evaluation in patien...
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation [0.03%]
与现有方法配合使用血液检测进行结直肠癌筛查对之前拒绝筛查者的影响：一项经济学评价
Shaun P Forbes,Elifnur Yay Donderici,Nicole Zhang et al.
Shaun P Forbes et al.
Aim: Inadequate adherence to colorectal cancer screening reduces individual and population level health benefits. Blood-based tests offer a new modality that may help patients overcome barriers, but there are concerns abo...
Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States [0.03%]
在美国 modeling mrna-1283疫苗的成本效益分析
Kelly Fust,Michele Kohli,Keya Joshi et al.
Kelly Fust et al.
Aims: COVID-19 disease burden in United States (US) adults ≥65 years and persons with underlying medical conditions remains high. This modeling study estimated the cost-effectiveness of the next-generation COVID-19 mRNA-...
Breaking barriers in women's pelvic health: claims-based economic analysis and healthcare utilization of an AI care program compared to usual care [0.03%]
突破女性盆底健康障碍：基于人工智能护理项目的经济效益和医疗利用率与常规护理的比较分析
Ana P Pereira,Andrea M Seet,Beatriz Domingues et al.
Ana P Pereira et al.
Aim: To compare healthcare utilization and spending among women enrolled in an employer-sponsored, artificial intelligence (AI) structured pelvic care program with those receiving usual in-person care for pelvic floor dys...
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States [0.03%]
美国镰状细胞病患者的EXAGAMLOGENE AUTOTEMCEL基因编辑治疗的 cost-effectiveness：对反复血管堵塞危机患者的分析
Andrea Lopez,Michael Gargano,Hongbo Yang et al.
Andrea Lopez et al.
Objective: Exagamglogene autotemcel (exa-cel) is a one-time nonviral gene-edited therapy approved in the United States (US) for treatment of patients aged ≥12 years with sickle cell disease (SCD) with recurrent vaso-occl...
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States [0.03%]
帕博利珠单抗辅助治疗可切除局部晚期头颈部鳞状细胞癌的经济学评估
Feng Qian,Arielle G Bensimon,Anjela Tzontcheva et al.
Feng Qian et al.
Aims: In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then contin...
Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis [0.03%]
医疗保险慢性偏头痛患者肉毒杆菌毒素和降钙素基因相关肽单克隆抗体的临床治疗转换及医疗费用：回顾性理赔分析
Yanan Dong,Ziling Mao,Annaliza Dominguez et al.
Yanan Dong et al.
Aims: Evaluate treatment switching and healthcare costs of onabotulinumtoxinA (onabotA) compared to calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for the preventive treatment of chronic migraine (CM)...